Maze Therapeutics disclosed topline Phase 2 results for MZE829, an oral APOL1 inhibitor targeting APOL1-mediated kidney disease and related patient subgroups. The company reported a clinically meaningful mean reduction in protein levels in urine measured by uACR, and said it will continue enrollment for its Phase 2 program while preparing for a pivotal pathway. In the Horizon study, Maze reported an average proteinuria reduction of 35.6% at week 12, with stronger responses in subgroups including those with focal segmental glomerulosclerosis. Analysts noted Vertex Pharmaceuticals’ inaxaplin as the benchmark for comparison, keeping expectations tied to how Maze’s results stack up across endpoints and populations. Despite the positive clinical signals, the stock moved lower, reflecting how quickly the market differentiates between biomarker progress and full pivotal de-risking for genetically defined kidney disease.